IL132502A0 - Improved methods for processing activated protein c - Google Patents

Improved methods for processing activated protein c

Info

Publication number
IL132502A0
IL132502A0 IL13250298A IL13250298A IL132502A0 IL 132502 A0 IL132502 A0 IL 132502A0 IL 13250298 A IL13250298 A IL 13250298A IL 13250298 A IL13250298 A IL 13250298A IL 132502 A0 IL132502 A0 IL 132502A0
Authority
IL
Israel
Prior art keywords
activated protein
improved methods
processing activated
processing
protein
Prior art date
Application number
IL13250298A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL132502A0 publication Critical patent/IL132502A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL13250298A 1997-04-28 1998-04-24 Improved methods for processing activated protein c IL132502A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4525597P 1997-04-28 1997-04-28
PCT/US1998/008384 WO1998048822A1 (fr) 1997-04-28 1998-04-24 Perfectionnement du traitement de la proteine c activee

Publications (1)

Publication Number Publication Date
IL132502A0 true IL132502A0 (en) 2001-03-19

Family

ID=21936854

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13250298A IL132502A0 (en) 1997-04-28 1998-04-24 Improved methods for processing activated protein c
IL13232598A IL132325A (en) 1997-04-28 1998-04-24 Activated protein c formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL13232598A IL132325A (en) 1997-04-28 1998-04-24 Activated protein c formulations

Country Status (35)

Country Link
US (4) US6159468A (fr)
EP (2) EP0875563A3 (fr)
JP (2) JP4383546B2 (fr)
KR (2) KR100564189B1 (fr)
CN (2) CN1235638C (fr)
AR (2) AR015598A1 (fr)
AT (1) ATE285788T1 (fr)
AU (2) AU740753C (fr)
BR (2) BR9809304B1 (fr)
CA (2) CA2287267C (fr)
CO (2) CO4950523A1 (fr)
CZ (1) CZ298429B6 (fr)
DE (1) DE69828330T2 (fr)
DK (1) DK0875252T3 (fr)
EA (2) EA004881B1 (fr)
EG (1) EG23685A (fr)
ES (1) ES2234072T3 (fr)
HK (1) HK1016472A1 (fr)
HU (2) HU224826B1 (fr)
ID (2) ID23172A (fr)
IL (2) IL132502A0 (fr)
IN (2) IN187157B (fr)
MY (2) MY120984A (fr)
NO (2) NO995134L (fr)
NZ (2) NZ500346A (fr)
PE (2) PE86299A1 (fr)
PL (2) PL195090B1 (fr)
PT (1) PT875252E (fr)
SI (1) SI0875252T1 (fr)
SV (2) SV1998000050A (fr)
TR (2) TR199902529T2 (fr)
TW (2) TWI242443B (fr)
UA (2) UA73071C2 (fr)
WO (2) WO1998048822A1 (fr)
ZA (2) ZA983496B (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048822A1 (fr) * 1997-04-28 1998-11-05 Eli Lilly And Company Perfectionnement du traitement de la proteine c activee
US6630137B1 (en) * 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
DE69930419T2 (de) * 1998-11-13 2006-09-07 Eli Lilly And Co., Indianapolis Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
JP2002530353A (ja) * 1998-11-20 2002-09-17 イーライ・リリー・アンド・カンパニー ウイルス性出血熱の処置法
DK1133314T3 (da) * 1998-11-23 2003-04-14 Lilly Co Eli Protein C til behandling af seglcellesygdom og thalassæmi
JP2002531519A (ja) * 1998-12-10 2002-09-24 イーライ・リリー・アンド・カンパニー 血栓性血小板減少性紫斑病および溶血性尿毒症性症候群の処置法
US6758938B1 (en) * 1999-08-31 2004-07-06 Micron Technology, Inc. Delivery of dissolved ozone
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
JP2004511428A (ja) * 2000-05-24 2004-04-15 イーライ・リリー・アンド・カンパニー 凝固亢進状態を処置するための製剤および方法
WO2002069232A2 (fr) 2001-02-19 2002-09-06 Merck Patent Gmbh Procede d'identification d'epitopes de lymphocytes t et utilisation dans la preparation de molecules a immunogenicite reduite
US7101982B2 (en) * 2001-03-30 2006-09-05 Immunex Corporation Control of ph transitions during chromatography
WO2003007686A2 (fr) * 2001-07-19 2003-01-30 Dmi Biosciences, Inc. Utilisation de chelateurs de cuivre pour inhiber l'inactivation de la proteine c
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
EP1453529A4 (fr) 2001-09-19 2007-09-26 Oklahoma Med Res Found Traitement de la sepsie avec tafi
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
IL161407A0 (en) 2001-10-15 2004-09-27 Chiron Corp Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (tfpi)
DE60232017D1 (de) 2001-12-21 2009-05-28 Novo Nordisk Healthcare Ag Flüssige zusammensetzung aus faktor vii polypeptiden
CA2475738A1 (fr) * 2002-03-08 2003-09-18 Eli Lilly And Company Formulations de proteines c activees
JP4648002B2 (ja) 2002-06-21 2011-03-09 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドの安定化された固体組成物
CA2502378A1 (fr) * 2002-10-29 2004-05-13 Alza Corporation Particules polypeptidiques solides stabilisees
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
ATE547114T1 (de) * 2003-06-25 2012-03-15 Novo Nordisk Healthcare Ag Flüssige zusammensetzungen von factor vii polypeptiden
JP2007532486A (ja) * 2004-03-17 2007-11-15 カイロン コーポレイション 組織因子経路インヒビターの投与による重度の市中肺炎の処置
WO2006014839A2 (fr) * 2004-07-23 2006-02-09 The University Of Rochester La proteine c activee inhibe les effets secondaires de l'activateur de plasminogene dans le cerveau
AU2006261555A1 (en) * 2005-06-23 2006-12-28 The University Of British Columbia Coagulation factor lll polymorphisms associated with prediction of subject outcome and response to therapy
WO2007139553A1 (fr) * 2006-05-31 2007-12-06 Genzyme Corporation Utilisation de polysaccharides pour faciliter une activité enzymatique
US20100041600A1 (en) * 2006-06-09 2010-02-18 Russel James A Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
EP2117514B1 (fr) * 2007-03-05 2011-06-15 Cadila Healthcare Limited Compositions comprenant des conjugués de peg-interféron alpha et de la raffinose en tant que cryoprotecteur
RU2476442C2 (ru) 2007-03-29 2013-02-27 Эббот Лэборетриз Кристаллические антитела против il-12 человека
TWI661833B (zh) * 2007-11-30 2019-06-11 百慕達商艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
CA2712057A1 (fr) * 2008-01-15 2009-07-23 The University Of British Columbia Proteine c rs2069915 en tant que predicteur de reponse de survie et administration de proteine c ou d'un compose de type proteine c active
EP2350649A4 (fr) * 2008-11-28 2012-11-14 Abbott Lab Compositions d'anticorps stables et procédés pour stabiliser celles-ci
WO2012068519A2 (fr) 2010-11-19 2012-05-24 Sirius Genomics Inc. Marqueurs associés à la réponse à une administration de la protéine c activée, et leurs utilisations
EP2702077A2 (fr) 2011-04-27 2014-03-05 AbbVie Inc. Procédé de contrôle du profil de galactosylation de protéines exprimées de manière recombinante
US9357765B2 (en) 2012-04-03 2016-06-07 Smiths Medical Asd, Inc. Heparain-bulking agent compositions and methods thereof
WO2013158273A1 (fr) 2012-04-20 2013-10-24 Abbvie Inc. Procédés de modulation de la distribution de variant de lysine c-terminal
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
RU2662564C2 (ru) 2012-07-04 2018-07-26 ЗЗ Байотек ЛЛС Лечение воспалительных заболеваний кожи
CA2883272A1 (fr) 2012-09-02 2014-03-06 Abbvie Inc. Procedes de controle de l'heterogeneite des proteines
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014159579A1 (fr) 2013-03-14 2014-10-02 Abbvie Inc. Anticorps anti-tnfα ayant mutés et leurs procédés d'utilisation
WO2014151878A2 (fr) 2013-03-14 2014-09-25 Abbvie Inc. Procédés pour la modulation des profils de glycosylation de protéines de traitements à base de protéines recombinantes au moyen de monosaccharides et d'oligosaccharides
EP3052640A2 (fr) 2013-10-04 2016-08-10 AbbVie Inc. Utilisation d'ions métaux pour la modulation des profils de glycosylation de protéines recombinantes
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (fr) 2013-11-15 2015-05-21 Abbvie, Inc. Compositions de protéines de liaison génétiquement glycomodifiées
AU2014391082B2 (en) 2014-04-16 2020-04-09 Zz Biotech Llc Treatment of abnormal cutaneous scarring
US11058750B2 (en) 2015-12-03 2021-07-13 Mor Research Applications Ltd. Compositions and methods for treatment of ocular diseases
EP4019007A1 (fr) * 2016-06-01 2022-06-29 Servier IP UK Limited Formulations d'oxyde de polyalkylène-asparaginase et leurs procédés de fabrication et d'utilisation
CN108159399B (zh) * 2017-12-29 2020-07-24 华中科技大学同济医学院附属同济医院 一种凝血蛋白酶aPC在防治糖尿病心肌病药物中的应用
WO2023119230A1 (fr) 2021-12-22 2023-06-29 L'oreal Compositions de modulation de la voie de coagulation et de la voie de nicotinamide-adénine dinucléotide et leurs procédés d'utilisation

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4849403A (en) * 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
AT399095B (de) * 1986-03-27 1995-03-27 Vukovich Thomas Dr Verfahren zur auftrennung von proteinen mittels gradientenelution und vorrichtung zur durchführung des verfahrens
US5175087A (en) * 1987-07-06 1992-12-29 Biopool International, Inc. Method of performing tissue plasminogen activator assay
CA1329760C (fr) * 1987-10-29 1994-05-24 Ted C. K. Lee Formulation de plasma et de proteines recombinantes dans des milieux a grande force ionique
US4877608A (en) * 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
JPH01226900A (ja) * 1988-03-08 1989-09-11 Green Cross Corp:The プロテインｃの精製方法
DE3823519A1 (de) * 1988-07-12 1990-01-18 Basf Ag Verfahren zur reinigung von aktiviertem protein c
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
WO1991012320A1 (fr) * 1990-02-09 1991-08-22 Zymogenetics, Inc. Proteine c activee a chaine legere tronquee
IL97312A (en) * 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5040862A (en) 1990-05-07 1991-08-20 Corning Incorporated Method of trimming optical power
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
US5413732A (en) * 1991-08-19 1995-05-09 Abaxis, Inc. Reagent compositions for analytical testing
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5395923A (en) * 1993-02-23 1995-03-07 Haemacure-Biotech, Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out"
JP3043558B2 (ja) * 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
JP2886061B2 (ja) * 1993-10-29 1999-04-26 財団法人化学及血清療法研究所 プロテインｃもしくは活性化プロテインｃの安定化方法及び安定化組成物
JPH07165605A (ja) * 1993-12-16 1995-06-27 Teijin Ltd 活性化プロテインｃバイアル
NZ270271A (en) * 1994-01-05 1996-07-26 Lilly Co Eli Minimizing protein c degradation
JPH08301786A (ja) * 1995-05-11 1996-11-19 Mochida Pharmaceut Co Ltd 吸収性骨疾患予防・治療剤
WO1997020043A1 (fr) 1995-11-30 1997-06-05 Zymogenetics, Inc. Production de proteine c chez des animaux transgeniques
WO1998048822A1 (fr) * 1997-04-28 1998-11-05 Eli Lilly And Company Perfectionnement du traitement de la proteine c activee
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
PL336889A1 (en) 2000-07-17
TR199902529T2 (xx) 2000-02-21
EA004881B1 (ru) 2004-08-26
NO995198D0 (no) 1999-10-25
TWI242443B (en) 2005-11-01
ID23172A (id) 2000-03-23
CO4940438A1 (es) 2000-07-24
JP4383546B2 (ja) 2009-12-16
US6159468A (en) 2000-12-12
MY118591A (en) 2004-12-31
NO995134D0 (no) 1999-10-21
CA2288143C (fr) 2012-08-21
IL132325A (en) 2005-07-25
EA002149B1 (ru) 2001-12-24
TR199902631T2 (xx) 2000-01-21
SI0875252T1 (en) 2005-06-30
PE84799A1 (es) 1999-09-16
NO995134L (no) 1999-12-21
WO1998048818A1 (fr) 1998-11-05
EA199900980A1 (ru) 2000-04-24
AU7258998A (en) 1998-11-24
ZA983496B (en) 1999-10-25
IN183798B (fr) 2000-04-15
DK0875252T3 (da) 2005-04-25
PE86299A1 (es) 1999-09-17
EG23685A (en) 2007-05-09
EP0875252A3 (fr) 2000-07-26
US6436397B1 (en) 2002-08-20
CO4950523A1 (es) 2000-09-01
HU224826B1 (en) 2006-02-28
HUP0100284A3 (en) 2003-08-28
US6395270B1 (en) 2002-05-28
CA2287267C (fr) 2006-08-15
AR012010A1 (es) 2000-09-13
ES2234072T3 (es) 2005-06-16
EP0875563A3 (fr) 2000-08-02
CA2287267A1 (fr) 1998-11-05
DE69828330D1 (de) 2005-02-03
PL195090B1 (pl) 2007-08-31
HUP0003401A2 (hu) 2001-02-28
JP2001527543A (ja) 2001-12-25
HK1016472A1 (en) 1999-11-05
HUP0100284A2 (hu) 2001-06-28
AU740753B2 (en) 2001-11-15
WO1998048822A1 (fr) 1998-11-05
BR9809304A (pt) 2000-10-17
ID22933A (id) 1999-12-16
PT875252E (pt) 2005-03-31
AU7161898A (en) 1998-11-24
HUP0003401A3 (en) 2003-01-28
KR100450856B1 (ko) 2004-10-02
SV1998000051A (es) 1998-12-11
CZ381099A3 (cs) 2000-03-15
PL195642B1 (pl) 2007-10-31
IN187157B (fr) 2002-02-16
ZA983497B (en) 1999-10-25
CN1254284A (zh) 2000-05-24
DE69828330T2 (de) 2005-10-13
UA73071C2 (en) 2005-06-15
KR20010020325A (ko) 2001-03-15
EP0875252A2 (fr) 1998-11-04
KR20010020242A (ko) 2001-03-15
EP0875563A2 (fr) 1998-11-04
ATE285788T1 (de) 2005-01-15
EP0875252B1 (fr) 2004-12-29
MY120984A (en) 2005-12-30
TW585871B (en) 2004-05-01
JP2001524111A (ja) 2001-11-27
CZ298429B6 (cs) 2007-10-03
EA199900979A1 (ru) 2000-06-26
CN1227025C (zh) 2005-11-16
BR9809292A (pt) 2000-07-04
IL132325A0 (en) 2001-03-19
US6162629A (en) 2000-12-19
NZ337828A (en) 2001-06-29
AR015598A1 (es) 2001-05-16
AU743531B2 (en) 2002-01-31
SV1998000050A (es) 1999-01-13
CA2288143A1 (fr) 1998-11-05
JP4383547B2 (ja) 2009-12-16
UA55448C2 (uk) 2003-04-15
NO995198L (no) 1999-10-25
AU740753C (en) 2002-10-10
PL336420A1 (en) 2000-06-19
CN1261280A (zh) 2000-07-26
CN1235638C (zh) 2006-01-11
BR9809304B1 (pt) 2011-02-08
KR100564189B1 (ko) 2006-03-27
NZ500346A (en) 2001-08-31

Similar Documents

Publication Publication Date Title
HUP0003401A3 (en) Improved methods for processing activated protein c
EP0904539A4 (fr) Inhibition d'interactions entre proteines
ZA9710338B (en) Proteins
GB9703681D0 (en) Protein complemention
GB9719879D0 (en) Protein
EP1018551A4 (fr) Proteine megsine
GB9715064D0 (en) Protein expression
PL344979A1 (en) Angiostatin-binding protein
ZA984322B (en) Sucrose-binding proteins
GB9720784D0 (en) Protein
GB9828880D0 (en) Protein
GB9519865D0 (en) Protein
GB9622436D0 (en) Protein
GB9812607D0 (en) Protein
GB9819038D0 (en) Protein
GB9809566D0 (en) Protein
GB9604865D0 (en) Modified proteins
GB9719670D0 (en) Protein
GB9720785D0 (en) Protein
GB9703103D0 (en) Protein
GB9609405D0 (en) Protein
EP0960198A4 (fr) Proteine de type cd44
GB9614293D0 (en) Modified proteins
GB9611896D0 (en) Modified proteins
GB9624028D0 (en) Modified proteins